Q1 EPS Forecast for Mersana Therapeutics Lowered by Analyst

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Equities researchers at Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.25) per share for the quarter, down from their previous forecast of ($0.24). Wedbush currently has a “Outperform” rating and a $4.00 target price on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.70) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $16.36 million during the quarter, compared to the consensus estimate of $7.71 million.

Several other equities analysts have also issued reports on MRSN. William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock. Citigroup started coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Mersana Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $4.25.

Mersana Therapeutics Stock Up 3.6 %

Shares of Mersana Therapeutics stock opened at $0.54 on Thursday. The stock’s 50-day moving average is $0.75 and its 200 day moving average is $1.54. Mersana Therapeutics has a one year low of $0.46 and a one year high of $6.28. The firm has a market cap of $67.24 million, a price-to-earnings ratio of -0.89 and a beta of 1.39. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC increased its holdings in shares of Mersana Therapeutics by 8.1% during the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after acquiring an additional 14,240 shares in the last quarter. US Bancorp DE acquired a new stake in Mersana Therapeutics in the 3rd quarter valued at $31,000. Dynamic Technology Lab Private Ltd bought a new stake in Mersana Therapeutics during the 3rd quarter valued at $34,000. Wells Fargo & Company MN increased its stake in Mersana Therapeutics by 40.3% during the 4th quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock valued at $97,000 after purchasing an additional 19,368 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in Mersana Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after buying an additional 25,058 shares during the last quarter. 93.92% of the stock is owned by institutional investors and hedge funds.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.